Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

5.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
5.7K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

1.1K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
1.1K
Hybridoma Technology01:31

Hybridoma Technology

15.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.3K
Antibody Structure01:10

Antibody Structure

61.3K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
61.3K
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

799
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
799
Antibody Structure and Classes01:25

Antibody Structure and Classes

4.1K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severity-associated cross-reactive anti-sarbecovirus antibody responses in COVID-19 convalescents and isolation of a dual-targeting monoclonal antibody with cross-neutralizing activity.

Frontiers in immunology·2026
Same author

Elevated BMI Is Not Associated With Adverse Outcomes in Open Airway Reconstruction.

The Laryngoscope·2026
Same author

Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Association between electrolyte disturbance score and 30-day severe disturbance of consciousness and in-hospital mortality in intensive care unit patients with intracerebral hemorrhage: A retrospective observational cohort study.

The Journal of international medical research·2026
Same author

The effect of acceptance and commitment therapy on negative emotions and quality of life in stroke patients: a systematic review and meta-analysis.

Frontiers in neurology·2026
Same author

Phytogenic Self-Conducting Flash Joule Heating Converts Rare-Earth Hyperaccumulator Biomass into Graphene Composites with Minimized Life-Cycle Impacts.

Environmental science & technology·2026

Related Experiment Video

Updated: Sep 12, 2025

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments
12:28

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments

Published on: October 15, 2016

11.6K

Engineering B cells to Express Fully Customizable Antibodies with Enhanced Fc Functions.

Chun Huang1, Atishay Mathur1, Chan-Hua Chang1

  • 1Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.

Biorxiv : the Preprint Server for Biology
|August 8, 2025
PubMed
Summary
This summary is machine-generated.

Genome editing of immunoglobulin heavy chain locus (IGH) enables B cells to produce custom Heavy chain only antibodies (HCAbs). This versatile platform allows engineering of Fc domains and antibody half-life for enhanced therapeutic potential.

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.7K
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

7.8K

Related Experiment Videos

Last Updated: Sep 12, 2025

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments
12:28

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments

Published on: October 15, 2016

11.6K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.7K
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

7.8K

Area of Science:

  • Immunology
  • Molecular Biology
  • Biotechnology

Background:

  • B cells naturally produce antibodies for immune responses.
  • Immunoglobulin heavy chain locus (IGH) is crucial for antibody structure and function.
  • Current antibody engineering methods have limitations in customization.

Purpose of the Study:

  • To reprogram B cells using genome editing to express custom Heavy chain only antibodies (HCAbs).
  • To engineer the constant (Fc) domain of HCAbs for enhanced effector functions and extended half-life.
  • To ensure HCAb homodimerization and prevent unwanted interactions with endogenous antibodies.

Main Methods:

  • Utilized genome editing techniques targeting the IGH locus in B cells.
  • Introduced specific mutations to customize Fc domains and antibody half-life.
  • Engineered mutations to enforce HCAb homodimerization and accommodate additional C-terminal domains.

Main Results:

  • Successfully reprogrammed B cells to express HCAbs with custom antigen-recognition domains.
  • Demonstrated the ability to engineer Fc domains for enhanced effector functions and extended antibody half-life.
  • Achieved obligate HCAb homodimerization and preferential expression of C-terminal domains in secreted isoforms.

Conclusions:

  • The HCAb editing platform offers significant flexibility for creating fully customized antibody molecules.
  • Engineered HCAbs leverage B cell properties for tailored therapeutic applications.
  • This approach expands the potential of B cells in antibody-based therapies.